In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Switching among biologic therapies is common practice in ... or loss of efficacy or adverse events associated with initial anti-TNF therapy. However, patients receiving TNF antagonist therapy ...

Three types of biologics used to manage UC include: anti-tumor necrosis factor (anti-TNF) agents integrin receptor antagonists (IRAs) interleukin (IL) inhibitors Anti-tumor necrosis factor (anti ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

It didn’t achieve that with Remicade and Enbrel, which were the first two anti-TNF biologics to face competition. In fact, Remicade took 28 months to reach the 80% target, and after 12 months ...

just over half were on anti-TNF agents while therapy for the rest was about equally divided between the IL-17 and IL-23 inhibitors. Other eligibility criteria included lack of previous biologic ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...